Fabrazyme
Named-patient access overview. Fabrazyme is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Fabrazyme (agalsidase beta) is Sanofi's recombinant enzyme replacement therapy for Fabry disease, an X-linked lysosomal storage disorder caused by alpha-galactosidase A deficiency. It has held FDA approval since 2003 and is one of the longest-established rare-disease enzyme replacement therapies. For Saudi Arabia patients with confirmed Fabry disease whose treating physician has recommended ERT, this page describes the SFDA Personal Importation Program pathway.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Fabrazyme
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Fabrazyme is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Fabrazyme in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Fabrazyme
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.